#United States #Columbus #gene therapy #Andelyn Biosciences #Dark Horse Consulting

Andelyn Biosciences Achieves Significant Certification in Gene Therapy Manufacturing

Andelyn Biosciences, a prominent player in the field of cell and gene therapy as a Contract Development and Manufacturing Organization (CDMO), recently announced a key achievement: full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) from Dark Horse Consulting. This certification recognizes Andelyn's capability to support advanced therapies with state-of-the-art quality and production systems, underscoring the organization's commitment to excellence in therapeutic manufacturing.

The ICMC program was developed to fill a gap in the industry's need for independent evaluation of CDMO capabilities. It establishes critical benchmarks for advanced therapeutics manufacturing, ensuring that organizations meet stringent global regulatory standards. Although selecting a CDMO can be a daunting task for therapeutic developers, the certification significantly streamlines this process by providing a solid framework that assures clients of their chosen partner's eligibility and reliability.

Wade Macedone, CEO of Andelyn Biosciences, stated, “The receipt of the ICMC certification reflects the strength of the teams, culture, and infrastructure we've built to support complex gene therapy programs.” In these times of ever-evolving therapeutic landscapes, having confidence in a manufacturing partner is pivotal, especially for sponsors chasing the dream of new treatments for patients.

The rigorous assessment backed by the ICMC program examines essential manufacturing site systems that encompass quality assurance, digital innovations, facilities and equipment standards, material handling, production efficacy, laboratory controls, and overall commercial readiness. This comprehensive evaluation allows for a transparent review of a CDMO's capabilities in critical areas, including technology transfer, Good Manufacturing Practice (GMP) compliance, and resource management.

Andelyn's success in achieving this certification underlines its ongoing investments in enhancing its advanced therapy program capabilities. These advancements encompass a variety of areas, such as viral vector manufacturing, plasmid production, process and analytical development, and quality control, as well as the integration of its innovative DIGITAL CDMO® platform which underpins all operations.

“We understand that gene therapy sponsors require partners who can deliver not only experience and reliable systems but also responsive customer service and scalable production capabilities,” explained Matt Niloff, Chief Commercial Officer of Andelyn Biosciences. His team has been proactive in ensuring that the ICMC certification serves as validation for the essential competencies required for successful gene therapy manufacturing. The certification is a beacon of trust for clients, assuring them of Andelyn's proficiency in navigating their programs through clinical and commercial manufacturing stages upon receiving the necessary approvals.

Importantly, the ICMC Certification is designed to be objective and does not function as an endorsement of specific CDMOs, nor does it replace the need for formal product- or customer-specific audits. Regardless, for Andelyn, this achievement is not merely a badge of honor, but a testament to their unwavering dedication to delivering top-notch quality and operational excellence.

Andelyn Biosciences itself boasts over 20 years of expertise in the field, having produced cGMP material for more than 500 clinical batches across 85 international clinical trials. Based in Columbus, Ohio, Andelyn is dedicated to accelerating the development and production of cell and gene therapies from concept to the final manufacturing stages, ensuring that they can bring innovative therapies to market swiftly and effectively. Clients benefit from their adaptable Curator® Cell and Gene Therapy Platforms that utilize data-driven approaches to enhance development and manufacturing processes.

In conclusion, Andelyn Biosciences' recent certification serves as a powerful affirmation of their operational capabilities within the gene therapy sector. With such validation and the backing of Dark Horse Consulting, Andelyn is poised to continue its mission of empowering innovators and elevating the standards in gene therapy manufacturing, bringing hope to patients worldwide in dire need of effective and transformative therapies.